Search Results
You are looking at 1 - 1 of 1 items for
- Author: Xavier Maldonado x
- Refine by access: All content x
Search for other papers by Nely Díaz-Mejía in
Google Scholar
PubMed
Search for other papers by David García-Illescas in
Google Scholar
PubMed
Search for other papers by Rafael Morales-Barrera in
Google Scholar
PubMed
Search for other papers by Cristina Suarez in
Google Scholar
PubMed
Search for other papers by Jacques Planas in
Google Scholar
PubMed
Search for other papers by Xavier Maldonado in
Google Scholar
PubMed
Search for other papers by Joan Carles in
Google Scholar
PubMed
Search for other papers by Joaquin Mateo in
Google Scholar
PubMed
Poly (ADP-ribose) polymerase (PARP) inhibitors have antitumor activity in advanced prostate cancer associated with loss of homologous recombination repair (HRR) function. About 20% of all patients with advanced prostate cancer present germline or tumor mutations in HRR-related genes, the most common being BRCA2, mutated in approximately 10% of all advanced prostate cancers. Challenges related to sample availability, tumor heterogeneity and access to NGS technology need to be addressed for a successful implementation of genomic stratification in routine clinical practice. The recent regulatory approvals of PARP inhibitors olaparib and rucaparib represent the first molecular biomarker-guided drugs for men with prostate cancer. While these findings represent a significant advance in the field of precision medicine and prostate cancer, there are still many unsolved questions on the optimal use of PARP inhibitors in this disease. Several clinical trials have shown that different mutations in various genes are associated with distinct magnitudes of sensitivity to PARP inhibitors, with BRCA2 mutations associating with more frequent and durable responses, questioning the benefit for subset of patients with mutations in other HRR-associated genes. In this review, we scrutinize the clinical development of different PARP inhibitors for the treatment of advanced prostate cancer, and we discuss how the study of additional biomarkers and the design of rational drug combinations can maximize patient benefit from this drug class.
